Please upgrade your browser.
The purpose of this investigational study is to better understand how vandetanib affects humans who have kidney cancer related to von Hippel-Lindau (VHL) disease, and to develop tests that may improve researchers understanding of kidney cancer and its effects.
Learn some basic facts about kidney cancer and how it is treated in this brief, informative, video provided by Novartis, a pharmaceutical company.
Right now, most cancer patients only have a few options for treatment. They can get chemotherapy or radiation in order to kill bad cells and stop them from dividing, and they can get surgery to cut out the disease.
More Americans are surviving childhood cancers than ever before, but many suffer lingering health problems as adults, a new study finds.
Cabozantinib is also in 45 ongoing or planned clinical trials, including pivotal Phase 3 trials in metastatic renal cell cancer (mRCC) in METEOR and advanced hepatocellular cancer (CELESTIAL).
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces...
Older people who need a kidney transplant are better off receiving an available organ from an older deceased donor rather than waiting for one from a younger donor, a new study shows.
Australian researchers report that an alternating regimen of sunitinib and everolimus, although feasible and low-risk in patients with advanced renal cell carcinoma (RCC), failed to meet the prespecified criteria for use or continued development.
Researchers identified two protein biomarkers— aquaporin-1 (AQP1) and perlipin-2 (PLIN2)— that were more than 95 percent accurate in detecting early-stage kidney cancers. The tests also didn’t result in any false-positives caused by non-cancerous kidney disease.
The seven-year study began in 2007 and the findings revolutionized the standard protocol for patient management in NCCS with an attenuated-dose regimen of sunitinib for patients with mRCC.
|Powered by NeonCRM|